Complex disputes
Precisely argued
A curated selection of matters illustrating the firm’s work in patent litigation, pharmaceuticals and life sciences, competition, unjust enrichment and technically complex commercial disputes.
Unipharm Ltd. v.
Sanofi S.A.
A Landmark Case in Patent Law, Competition and Unjust Enrichment
Presented separately as the firm’s central showcase matter, with a litigation timeline spanning the District Court, the Supreme Court and the Further Hearing.
Explore the matter → District Court 2015 (PDF) → Supreme Court 2021 → Further Hearing 2023 (PDF) →Bayer v. Unipharm
Patent opposition concerning crystalline sorafenib tosylate. The application was refused for lack of inventive step and Bayer’s appeal was dismissed by the Tel Aviv District Court.
View matter → Read judgment (PDF) →GlaxoSmithKline — Momelotinib
Oppositions to two related patent applications concerning crystalline Form II of momelotinib, addressing inventive step, sufficiency of disclosure and claim support under sections 5, 12 and 13 of the Patents Law.
View matter → Read decision (PDF) →Bristol-Myers Squibb — Eliquis
Patent term extension proceedings concerning the effect in Israel of cancellation of a UK reference patent extension. The District Court dismissed the appeal; an application for leave to appeal is pending before the Supreme Court.
View matter → Read judgment (PDF) →GlaxoSmithKline — Paroxetine
Patent opposition concerning paroxetine and the “disappearing polymorph” issue, including scientific evidence and disclosure before the Patent Office.
View matter → Read decision (PDF) →Merck — Fosalan
Patent opposition concerning once-weekly alendronate dosing and inventive step.
View matter → Read decision (PDF) →Lundbeck — Cipralex
Proceedings concerning patent term extension for escitalopram.
View matter → Read decision (PDF) →Camtek v. Orbotech
Technically complex patent proceedings outside pharmaceuticals, demonstrating broader technology litigation experience.
View matter →